Transforming life for people living with Parkinson’s and other CNS disorders

LATEST PRESS RELEASES
JULY 10, 2024 / REGULATORY

IRLAB publishes interim report for the period January-June 2024

Gothenburg, Sweden, July 10, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company’s interim report for the period January-June 2024, has been publihed.

Read More >

Watch IRLAB’s
Capital Markets Day 2023!

IRLAB A
16.25
SEK
TODAY
4.50 %
TODAY SEK
0.70 SEK
16:00:00
2024-07-22
More share info >

ISP – The proprietary technology platform

IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.

IRLAB’s clinical phase II candidates

Mesdopetam (IRL790)

In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.  

Pirepemat (IRL752)

In development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease.

LATEST PRESENTATION
MARCH 7, 2024

Fireside chat with Viktor Siewertz, CFO, at ABGSC

Viktor Siewertz, CFO, participated in the ABGSC fireside chat, moderated by Alexander Krämer, analyst at ABGSC, The event was recorded on March 5 and published on March 7, 2024.

Read More >